Rapid Dose Therapeutics Corp

Rapid Dose Therapeutics Corp

0.06
USD
-0.02
(-21.10%)
-0.02EPS
11.75MMarket Cap

Total Valuation

USD

As of August 31, 2026, Rapid Dose Therapeutics Corp carries a market capitalization of 11.75M, placing it among publicly traded companies globally. Its enterprise value stands at 15.82M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap11.75M
Enterprise Value15.82M

Share Statistics

As of August 31, 2026, Rapid Dose Therapeutics Corp has 137.78M shares outstanding.

Shares Outstanding137.78M

Valuation Ratios

These figures are as of August 31, 2026. The price-to-sales ratio is 7.52, and the price-to-book ratio stands at -1.99.

PS Ratio7.52
PB Ratio-1.99
P/TBV Ratio-1.99
P/FCF Ratio5.47
P/OCF Ratio43.51

Enterprise Valuation

These figures are as of August 31, 2026. The EV/Sales ratio of 10.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 15.82M versus a market cap of 11.75M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales10.35

Financial Position

As of August 31, 2026, Rapid Dose Therapeutics Corp maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -68.89, indicating conservative leverage, while an interest coverage ratio of -1.10 demonstrates limited ability to service its debt obligations.

Current Ratio0.03
Quick Ratio0.02
Debt / Equity-68.89
Debt / EBITDA-4.06
Interest Coverage-1.10

Financial Efficiency

These figures cover the twelve months ended August 31, 2026. Return on assets (ROA) is negative at -87.55, reflecting losses generated across the asset base. Inventory turnover of 7.97 indicates how many times Rapid Dose Therapeutics Corp sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-87.55
Inventory Turnover7.97

Stock Price Statistics

USD

As of the close on November 9, 2026, Rapid Dose Therapeutics Corp's stock has declined approximately 61.87% over the past 52 weeks. The 50-day moving average sits at 0.08, while the 200-day moving average is 0.22.

52-Week Price Change-61.87%
50-Day Moving Average0.08
200-Day Moving Average0.22

Income Statement

USD

Over the twelve months ended August 31, 2026, Rapid Dose Therapeutics Corp generated 1.53M in revenue and converted that into -2.27M in net income, yielding earnings per share of -0.02. EBITDA reached -1.00M, while operating income came in at -1.35M.

Revenue1.53M
Gross Profit751,147.21
Operating Income-1.35M
Pretax Income-2.27M
Net Income-2.27M
EBITDA-1.00M
EBIT-1.35M
Earnings Per Share (EPS)-0.02

Balance Sheet

USD

As of August 31, 2026, Rapid Dose Therapeutics Corp holds 6,225.05 in cash and equivalents against 4.08M in total debt, resulting in a net debt position of 2.53M. Total book value stands at -5.92M, with working capital of -6.50M providing operational flexibility.

Cash & Cash Equivalents6,225.05
Total Debt4.08M
Net Debt2.53M
Equity (Book Value)-5.92M
Book Value Per Share-0.04
Working Capital-6.50M

Cash Flow

USD

Rapid Dose Therapeutics Corp produced 264,238.96 in operating cash flow over the twelve months ended August 31, 2026. After subtracting 1.84M in capital expenditures, free cash flow totaled 2.10M - equivalent to 0.02 per share.

Operating Cash Flow264,238.96
Capital Expenditures1.84M
Free Cash Flow2.10M
FCF Per Share0.02

Margins

Over the twelve months ended August 31, 2026, Rapid Dose Therapeutics Corp posted a gross margin of 49.12, reflecting its pricing power and cost economics. The operating margin of -88.50 and net profit margin of -148.27 provide insight into operational efficiency.

Gross Margin49.12
Operating Margin-88.50
Pretax Margin-148.27
Profit Margin-148.27
EBITDA Margin-65.67

Dividends & Yields

These figures cover the twelve months ended August 31, 2026. Free cash flow yield stands at 18.29, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 18.29, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Rapid Dose Therapeutics Corp shareholders.

Shareholder Yield18.29
FCF Yield18.29

Scores

As of August 31, 2026, Rapid Dose Therapeutics Corp has an Altman Z-Score of -27.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-27.77